Airborne pathogen simulants and mobility testing
Airborne pathogen mobility and the airborne mobility of respiratory droplets, such as saliva, and testing thereof, can be monitored by tracking detectable compounds and measuring concentrations.
1. A method of distributing a saliva simulant, comprising:
receiving the saliva simulant, wherein the saliva simulant comprises water, a DNA taggant, and a carrier, and wherein the saliva simulant simulates human emission of a target pathogen;
spraying the saliva simulant in air at a first release location in a determined release amount, to be detected at a first collection location, wherein a detected amount of the saliva simulant detected at the first collection location relative to the determined release amount is indicative of a degree of airflow from the first release location to the first collection location;
collecting a sample at the first collection location;
determining a tracer concentration at the first collection location based on the detected amount of the saliva simulant detected at the first collection location;
determining a scale that correlates tracer concentrations to inhalation probabilities and/or viral load;
based on the collected amount and/or the tracer concentration, and based on the scale, determining an infection risk value representing infection risk in an enclosed space diagnostic of infection by the target pathogen; and
generating a report displaying a first graphic element representing the infection risk value and displaying a second graphic element representing the detected amount of the saliva simulant at the first collection location in a map comprising the first release location and the first collection location.
2. The method of claim 1 , wherein the first release location and the first collection location are distinct locations in a building and are separated, at least in part, by a portion of a building layout that blocks airflow and wherein the first release location and the first collection location are such that measurable airflow occurs from the first release location to the first collection location, flowing around the portion of the building layout that blocks the airflow.
3. The method of claim 1 , wherein the first release location and the first collection location are both within a confined space in a building, the method comprising releasing the saliva simulant at the first release location at a first time and collecting a portion of released saliva simulant at the first collection location at a second time, wherein the second time is after, and distinct from, the first time.
4. The method of claim 1 , further comprising:
mapping a plurality of collection locations;
mapping a plurality of release locations;
releasing a selected DNA taggant at a release location;
collecting droplet and/or aerosol sample at a collection location of the plurality of collection locations; and
quantifying DNA concentrations at collection locations using qPCR.
5. The method of claim 4 , wherein at least some of the plurality of release locations are mobile and simulate dispersing while moving.
6. The method of claim 4 , wherein releasing comprises releasing a plurality of releases using a plurality of DNA taggants or combinations thereof.
7. The method of claim 1 , wherein spraying the saliva simulant at the first release location comprises spraying the saliva simulant out into an airspace at a rate that corresponds to saliva dispersion of a human into the airspace resulting from the human coughing, sneezing, talking, yelling, and/or singing.
8. The method of claim 1 , wherein the target pathogen is SARS-Cov-2, the carrier is bound to the DNA taggant via a carrier polysaccharide and/or one or more protein to form particles in solution having diameters of 0.01 μm to 100 μm, and one or more additional carriers to form a saliva simulant solution containing around 99% H 2 O, and around 1% of a mixture of polysaccharides, proteins, salt and DNA taggants.
9. The method of claim 8 , wherein the particles in solution have diameters of 0.1 μm to 1 μm.
10. The method of claim 1 , further comprising collecting an air sample from an ambient environment at the first collection location with a vacuum apparatus having a vacuum flow rate that matches human breathing, collecting through a filter connected to the vacuum apparatus, the filter having a pore size suitable for filtering the saliva simulant from the air sample.
11. A method of detecting a pathogen simulant, comprising:
determining a plurality of collection locations to receive at least a portion of the pathogen simulant released in air, wherein the pathogen simulant comprises water, a DNA taggant, and a carrier, the pathogen simulant simulating human emission of a target pathogen, the plurality of collection locations including a first collection location;
determining a release amount, at least approximately, of the pathogen simulant released in air at a first release location;
collecting a sample at the first collection location of the plurality of collection locations;
determining a collected amount of the pathogen simulant in the sample;
determining a tracer concentration at the first collection location based on the collected amount;
determining a scale that correlates tracer concentrations to inhalation probabilities and/or viral load; and
based on the collected amount and/or the tracer concentration, and based on the scale, determining an infection risk value representing infection risk in an enclosed space diagnostic of infection by the target pathogen.
12. The method of claim 11 , further comprising:
releasing a first amount of the pathogen simulant in air at a first location of the plurality of collection locations;
recording an indication of the first amount;
measuring a second amount of the pathogen simulant in the sample collected at a second location that is different from the first location; and
generating a report displaying a first graphic element representing the first amount of the pathogen simulant at the first location and displaying a second graphic element representing the second amount of the pathogen simulant at the second location in a map comprising the first location and the second location.
13. The method of claim 11 , wherein the target pathogen is SARS-Cov-2.
14. The method of claim 11 , wherein the carrier comprises polysaccharides, proteins, salt, or a combination thereof.
15. The method of claim 14 , wherein the pathogen simulant comprises the DNA taggant bound to a carrier polysaccharide and/or one or more protein to form particles in solution having diameters of 0.01 μm to 100 μm.
16. The method of claim 15 , wherein the pathogen simulant comprises one or more additional carriers to form a pathogen simulant solution containing around 99% H 2 O, and around 1% of a mixture of polysaccharides, proteins, salt and DNA taggants.
17. The method of claim 15 , wherein the particles in solution have diameters of 0.1 μm to 1 μm.
18. The method of claim 11 , wherein the pathogen simulant is a simulant with a behavior corresponding to human aerosol emission and/or human droplet emission.
19. The method of claim 11 , wherein the pathogen simulant is a simulant with a behavior corresponding to human droplet emission followed by at least partial evaporation to become aerosolized.
20. The method of claim 11 , wherein collecting the sample comprises collecting an air sample from an ambient environment with a vacuum apparatus with a vacuum flow rate that matches human breathing through a filter connected to the vacuum apparatus, the filter having a pore size suitable for filtering the pathogen simulant from the air sample.
21. A method of measuring reduction of potential pathogens in an enclosed space, comprising:
determining a plurality of collection locations in the enclosed space to receive at least a portion of a pathogen simulant released in air, wherein the pathogen simulant comprises water, a DNA taggant, and a carrier, the pathogen simulant simulating human emission of a target pathogen, the plurality of collection locations including a first collection location;
determining a release amount, at least approximately, of the pathogen simulant released in air at a first release location in or around the enclosed space;
collecting a sample at the first collection location of the plurality of collection locations;
determining a collected amount of the pathogen simulant in the sample;
determining a tracer concentration at the first collection location based on the collected amount;
determining a scale that correlates tracer concentrations to inhalation probabilities and/or viral load;
based on the collected amount and/or the tracer concentration, and based on the scale, determining an infection risk value representing infection risk in the enclosed space diagnostic of infection by the target pathogen;
based on the infection risk value, as measured over a plurality of times, determining a recovery time for the enclosed space.
22. The method of claim 21 , wherein the recovery time corresponds to a time over which the tracer concentration reduces by a predetermined reduction ratio.
23. The method of claim 22 , wherein the predetermined reduction ratio is a ratio of 10 −4 or less, representing a reduction in the tracer concentration over the recovery time by a factor of at least 10 4 .